CURE’s ovarian cancer page is a go-to resource for oncology news and updates in the world of ovarian cancer Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in ovarian cancer.
February 24th 2021
Two evaluations for treatment responses in women with ovarian, fallopian tube or primary peritoneal carcinoma may need to take into consideration other factors such as other existing conditions.
February 14th 2021
A cancer survivor remembers his wife who died of complications from ovarian cancer on Valentine’s Day several years ago. His advice to everyone: Holidays gradually become positive reflections of all that was good before cancer took it away.
February 8th 2021
Diane Powis spent more than 10 months bouncing from one doctor to the next before finally being “blindsided by” a diagnosis of stage 3 ovarian cancer. But as her initial feelings of isolation and fear wore off, Powis soon learned that she wasn’t alone – and that help and information were out there.
February 6th 2021
At the moment it may be hard to realize, but your life is not over because of cancer.
February 4th 2021
In this episode of the “CURE® Talks Cancer” podcast, we spoke with a patient who was blindsided by her stage 3 ovarian cancer diagnosis several years ago. We talk about how she spent months going from specialist to specialist before finally receiving her diagnosis, and why she dedicates much of her time to advocating for others.
January 22nd 2021
Women who reported using oral contraceptives had a decreased risk of endometrial and ovarian cancer, compared to those who never used the hormone medications. The data also indicated the association extended up to three decades after patients stopped using the contraceptives.
January 16th 2021
It’s okay for me to not feel like celebrating my 5-year cancerversary in a world that is upside down and backward because of COVID-19. Yes, I’m grateful and blessed, but I’m not bullet-proof. I’m human. I don’t have to feel guilty. None of us do.
January 8th 2021
In an interview with CURE®, the “Felicity” and “Scandal” actor spoke about his experience as a caregiver to his mother, and why women should not just watch and wait for their ovarian cancer to recur.
January 5th 2021
A gynecologic oncology expert from the University of California, Davis reviewed early-stage ovarian cancer and the importance of knowing what options are available before, during and after treatment.
January 4th 2021
A roundup of some ovarian cancer news and updates that occurred in 2020 that patients may have missed.
December 28th 2020
Women with ovarian cancer report a better quality of life when treated with a combination of Keytruda, Avastin and oral metronomic cyclophosphamide.
December 22nd 2020
Keytruda (pembrolizumab), Avastin (bevacizumab) and cyclophosphamide contributed to a clinical benefit in 95% of women in the trial and a durable treatment response of 12 months or longer in 25% of women.
October 17th 2020
Watch the entire Ovarian Cancer Heroes program right here!
October 17th 2020
An oncology nurse, patient turned advocate and cancer biologist were honored during CURE®’s third annual Ovarian Cancer Heroes program where they got to share messages of resiliency with a virtual audience.
October 6th 2020
Time is a valuable commodity, especially for patients with cancer who may find themselves with limited time or limited free time to enjoy the things they loved prior to their cancer. But the COVID-19 pandemic is robbing patients of that precious time.
September 29th 2020
Five-year follow-up data from the phase 3 SOLO-1 trial demonstrates a nearly five-year delay in disease progression with Lynparza compared with a delay of just over a year with placebo in women with newly diagnosed, advanced ovarian cancer harboring a BRCA gene mutation.
September 28th 2020
A weekly high dose of chemotherapy did not improve survival for patients with epithelial ovarian cancer, though the treatment regimen was effective and well-tolerated.
September 11th 2020
A proposed preventive surgery that would take out fallopian tubes before menopause but save ovary removal until afterwards was favored by most premenopausal previvors of ovarian cancer in a study.
September 11th 2020
The study results also showed that older age was significantly associated with lower cancer genetics knowledge, which, according to a post-doctoral research fellow at Dana-Farber Cancer Institute, is important because older adults may serve as a resource for family members who seek information about their family's health history.
September 10th 2020
Compared to physician’s choice of chemotherapy, the MEK inhibitor Mektovi failed to improve progression-free survival in patients with low-grade serous ovarian carcinomas. However, the study authors note Mektovi demonstrated promising results that support continued use of the treatment.
September 8th 2020
The National Ovarian Cancer Coalition to host its annual "Together in Teal®" No Boundaries National Broadcast Celebration During September awareness month on Saturday, Septemeber 26, 2020.
September 3rd 2020
Immediate treatment with Lynparza after standard surgery and chemotherapy should be considered for all patients with newly diagnosed stage 3 or 4 ovarian cancer that carries a BRCA gene mutation, even if residual disease remains, researchers have found.
August 28th 2020
Nearly half (48%) of the patients reported experiencing significant fatigue following their surgery. Thirty-nine percent of the patients still reported significant fatigue one year following their surgery.
August 27th 2020
Here is a list of the recent trial initiations that occurred within the cancer space in August.
August 18th 2020
While 75% of patients with gynecological cancers and COVID-19 will recover, new data from New York City shows specific risks for patients with cancer infected with COVID-19.
August 3rd 2020
A roundup of the latest news and updates for patients with ovarian cancer from CURE®.
July 14th 2020
Although the study failed to meet its goal of progression-free survival, overall survival data are currently not yet available, and follow-up will continue until the next planned analysis.
July 14th 2020
Ten percent of women who received a hysterectomy and salpingectomy, or removal of the fallopian tubes, during the study period had a family history of breast or ovarian cancer.
July 13th 2020
A recent data analysis found that most women diagnosed with ovarian cancer (92%) experienced abdominal and pelvic-related symptoms and visited a physician with this complaint anywhere from six to 70 months prior to diagnosis.